MPPE1 and melanoma: We next tested therapeutic efficacy of cDC1 administration in established ID engrafted B16/F10 melanoma, a very aggressive tumor that does not express exogenous or dominant Ags and is largely refractory to anti-PD-1 therapy [28, 43].